Actigraphy is increasingly incorporated into clinical practice to monitor intervention effectiveness and patient health in congestive heart failure (CHF). We explored the prognostic impact of actigraphy-quantified physical activity (AQPA) on CHF outcomes. PubMed and Medline databases were systematically searched for cross-sectional studies, cohort studies or randomised controlled trials from January 2007 to December 2017. We included studies that used validated actigraphs to predict outcomes in adult HF patients. Study selection and data extraction were performed by two independent reviewers. A total of 17 studies (15 cohort, 1 cross-sectional, 1 randomised controlled trial) were included, reporting on 2,759 CHF patients (22-89 years, 27.7% female). Overall, AQPA showed a strong inverse relationship with mortality and predictive utility when combined with established risk scores, and prognostic roles in morbidity, predicting cognitive function, New York Heart Association functional class and intercurrent events (e.g. hospitalisation), but weak relationships with health-related quality of life scores. Studies lacked consensus regarding device choice, time points and thresholds of PA measurement, which rendered quantitative comparisons between studies difficult. AQPA has a strong prognostic role in CHF. Multiple sampling time points would allow calculation of AQPA changes for incorporation into risk models. Consensus is needed regarding device choice and AQPA thresholds, while data management strategies are required to fully utilise generated data. Big data and machine learning strategies will potentially yield better predictive value of AQPA in CHF patients.
Introduction
Cardiovascular disease (CVD) is the most common cause of death in Europe despite the substantial decrease in its mortality rates over the last decade. 1 In 2012, it was the most common cause of death in women and second most in men in the UK. 2 National Health Service (NHS) England spent £6.4b in the financial year 2012-13, representing a huge economic burden. 2 Congestive heart failure (CHF) holds the greatest burden with 30-40% mortality at 1-year 3, 4 and makes up 1-2% of the annual healthcare budget in Western countries. 5, 6 There has been a surge in uptake of cardiac rehabilitation programmes in the UK, which focuses on improving physical activity (PA) as PA has been shown to be a predictor of premature CVD-associated morbidity and mortality, 7 with risk reduction attributed to, amongst other effects, increased cardiac output through left ventricular dilatation and hypertrophy and decreased arterial stiffness through oxidative stress reduction and release of vasodilatory mediators. 8 The role of PA is two-fold: not only does a lack of PA act as a risk factor of CVD, but it also acts as a quantitative parameter of effectiveness of the interventions designed to improve PA in CVD patients. There exists a substantial amount of prospective clinical evidence for both sedentary behaviour and moderate-to-vigorous PA (MVPA) with regards to CVD events in non-CVD patients. Several reviews have found that sedentary behaviour consistently increases the risk of both non-fatal and fatal CVD events in the general adult population. [9] [10] [11] [12] Conversely, PA level has been shown to be inversely related to CVD risk in non-CVD populations by multiple prospective studies, [13] [14] [15] including the Whitehall II study. 16 Indeed, MVPA has been used as the basis for PA guidelines by the American College of Sports Medicine/American Heart Association for adults, 17 with other PA guidelines developed to improve cardiovascular health in the general population. 18 These findings hold true for CHF patients. In a population of black adult men, a dose-response relationship is seen between increasing MVPA levels and protection from heart failure hospitalizations. 19 Evidence from male participants belonging to a Swedish populationbased cohort suggested that both extremities of PA compared with moderate levels could increase the risk of heart failure in men. 20 Recognizing such evidence, PA has been incorporated into management plans as formal cardiac rehabilitation or exercise training following CVD events. Strategies used to quantify PA involve subjective (or indirect) measurements, using self-reported techniques, which are in the form of questionnaires and interviews. These techniques are widely used due to their cost-effectiveness, low patient burden, and practicality. These have been reported to be less reliable, as shown by Healy et al. 21 who report a wide range of test-retest correlation coefficients, Fjeldsoe et al. 22 observing variation in PA recall depending on participants' activity levels, and Tomaz et al. 23 showing overestimation of vigorous PA.
The subjective nature of these strategies predispose participants to recall and response biases, which lead to the over-or underestimation of PA data, 24 and results in weak correlation to CVD outcomes. 25, 26 An alternative strategy is therefore needed to objectively and representatively quantify PA. Technological advancement has given rise to actigraphs-a small device worn on various parts of the body (most commonly the hip or wrist)-that monitors human activity. 27 It generally consists of three main components: (i) a piezoelectric or capacitive accelerometer, a device that measures acceleration, (ii) on-board memory to store recorded values, and (iii) a wired or wireless interface from which data can be downloaded. 28 Actigraphs measure acceleration along multiple axes, which allow for the quantification of step and activity count, and for posture to be detected. 27, 29 Taken together, these data are more meaningful than subjective and objective PA measurements using CPET, as it allows for the situational contextualization of PA. There is therefore potential for actigraphs to be incorporated in clinical practice, as their multifunctionality means that they can more accurately and consequentially predict CVD outcomes and monitor the effectiveness of cardiac rehabilitation programmes. Physicians can provide appropriate advice to patients, and patients can take responsibility of their own health monitoring. The utility of actigraphs is increasingly recognized, demonstrated by top industry players' interest in the actigraph device market. Whilst there is a great amount of literature on the predictive role of subjectively measured PA in CVD events, [30] [31] [32] there is limited literature on the predictive role of objectively measured PA, with only a review looking at the clinical utility of actigraphs in CHF. 33 Recognizing the significance of actigraphs in the future of cardiovascular medicine, we aim to review the predictive value of actigraphs in CHF patients, as expenditure on this group of CVD patients poses the highest economic burden. Therefore, this systematic review aims to provide a comprehensive overview of all studies in the past 10 years measuring the prognostic value of actigraphy-quantified physical activity (AQPA) mortality, morbidity, and health-related quality of life (HRQoL) outcomes of CHF patients, provide insight into measurement techniques and protocols of actigraphy studies, and create a framework to provide recommendations for future work.
Methods

Search strategy
This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. 34 PubMed and Medline databases were searched between January 2007 and December 2017 to capture studies performed in the last 10 years to reflect contemporary device usage using a search algorithm detailed in the Supplementary material online, S1. References of selected papers were manually searched to ensure maximum coverage.
Two reviewers (M.T. and J.W.) independently performed the literature search, removed duplicates by title review, and reviewed the abstracts and full texts to determine the inclusion of studies according to the pre-determined criteria. The final list of included studies from both reviewers were then merged, and conflicts between reviewers were discussed in person with a third reviewer (O.J.) until agreement was reached.
Inclusion and exclusion criteria
An initial literature review was performed to determine the scope of available literature and pre-determine inclusion and exclusion criteria. Both non-randomized and randomized controlled trials (RCTs) in English reporting the prognostic impact of AQPA on morbidity (defined as functional impairment or intercurrent events), mortality, or HRQoL as measured by validated instruments [e.g. Kansas City Cardiomyopathy Questionnaire, Minnesota Living with Heart Failure (MLHF) score] in adult CHF were considered in this review. Both wearable or implantable accelerometers were included. Case studies or case series, and studies reporting on children (<18-year-old) and on devices which only measured other physiological parameters (e.g. electrocardiography) were excluded.
Outcomes of interest and data extraction
Data from included studies were independently extracted by two reviewers (M.T. and J.W.). The two datasets were combined and any conflict between reviewers was discussed in person with a third reviewer (O.J.) until agreement was reached.
The following data were extracted: author, publication year, study period (defined as period in which patients were recruited), study design and research question, number of patients and their characteristics, device used, PA measurement duration and time points of measurement, PA analysis method, primary outcome measured and
main findings relating primary outcomes to AQPA. Authors of the included studies were contacted if the data required was not found in the published literature.
Risk of bias assessment
Risk of bias assessment was performed using the Newcastle-Ottawa scale for non-randomized studies. Assessment of RCTs was performed using the Cochrane Risk of Bias tool. These scores were then converted to the Agency for Healthcare Research and Quality (AHRQ) standards, with studies rated as 'poor', 'fair', or 'good quality'.
Results
Selected studies
The literature search identified 406 studies, of which 98 were duplicates. From the 308 studies reviewed, 17 were included [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] ( Figure 1) . Data from these studies are summarized in the Supplementary material online, Table S1 .
Study objectives, designs and population
All studies observed the prognostic impact of objectively measured PA in CHF. Thirteen were prospective cohort studies, [35] [36] [37] [38] [39] [40] [41] [42] [44] [45] [46] 49, 51 two were retrospective cohort studies, 47, 48 and one was cross-sectional. 43 The remaining study was an ancillary study using patients from a RCT. 50 These studies recruited a total of 2759 patients but only 2270 (82.3%) were included in the analyses due to technical difficulties precluding complete datasets from being collected from the excluded patients.
Risk of bias assessment
Studies included in this review were generally of good quality. According to the AHRQ standards, two studies were rated 'poor' (11.8%), one study was rated 'fair' (5.9%), and 15 studies were rated 'good' (82.4%).
Devices used
A total of 12 different devices were used and are detailed in Table 1 (readers are invited to review the reliability of most of these devices in a previous review by Van Remoortel et al.
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). Six were triaxial, one was biaxial, four were uniaxial, and one was omnidirectional. Ten devices were worn on either the wrist (n = 2) or waist (n = 8), with one worn on both. An implantable cardioversion device or cardiac resynchronization therapy defibrillator that monitored PA was used in one study. 40 
Physical activity quantification methods
Four main methods of quantifying PA were used: activity counts stratified by intensity, vector magnitudes and frequencies, walking parameters, and metabolic equivalent of task (MET). Three studies by Alosco et al. [36] [37] [38] used both walking parameters and activity counts to quantify PA. One study did not report its activity analysis method 39 and another study only considered movement-related activity duration as a percentage of 24 h. 51 Actigraphy data was stratified according to activity levels which had different definitions across studies.
Activity counts stratified by intensity
Non-specific uniaxial ActiGraph activity counts were used by eight studies to quantify PA and stratify activity by intensity. 
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Further discrepancies arose in defining moderate and vigorous intensity PA. Loprinzi's group combined the two activity levels, considering >2020 counts/min to be MVPA. 47, 48 Alosco et al. [36] [37] [38] observed two moderate intensity PA levels based on calibration studies, namely Matthew's moderate intensity between 760 and 5724 counts/ Figure 1 Study selection process.
Can activity monitors predict outcomes in patients with heart failure?
. 55 These studies defined vigorous intensity PA to be >5724 counts/min. Melin et al. 45 was the sole study, which determined intra-individual variability through quantifying the kurtosis and skewness of actigraphy data.
Vector measurements
Three studies considered vector magnitudes and frequency per minute. 40, 46, 50 If a pre-defined threshold was reached, this was considered an active minute. Conraads et al. 40 was the only study that used implanted devices, which measured the number of minutes the patient is active per day. A patient was considered 'active' if pre-determinedthresholds of both number and magnitude of accelerometer deflections were reached. Waring et al. 46 used a triaxial accelerometer, calculating the sum of vector magnitude units (VMUs) from three planes of movement per minute. This study defined the threshold for higher-intensity PA to be > _3000 VMUs and dichotomized their patients into more active (> _60 min of higher-intensity activity) and less active (<60 min) groups. Finally, Snipelisky et al. determined activity using 'arbitrary accelerometer units', which were determined by cumulative triaxial vector measurements, averaging values obtained in 15-min epochs to give average daily accelerometer units. All epochs with >50 units were also averaged to give hours active per day. 50 Walking parameters Daily step counts are one of the simplest PA measurements and were used in six studies. [35] [36] [37] [38] 42, 43 All used a daily step count averaged over the measurement period to categorize patients into different PA levels based on predefined step counts. Walking speed was used in a study by Jehn et al. 44 to distinguish New York Heart Association (NYHA) functional class. This was achieved by quantifying the total amount of time spent in each activity level: 'passive' (not defined), 'active' (not defined), 'walking' (0-80 m/ min), and 'fast walking' (83-115 m/min).
Metabolic equivalent of task
Two studies converted sensor data to MET values, 41, 49 which expresses the energy cost of PA. Studies using METs mostly utilized proprietary software, and therefore unique algorithms, related to the specific accelerometer used. Howell et al. 41 used the Actical with the following algorithm: METs = 2.384 þ (0.0007341 Â activity counts). 56 Miyahara et al. 49 determined METs every 10 s before stratifying patients into high (>8.4 MET-hours) or low activity (<8.4 METhours) groups.
Prognostic impact of actigraphyquantified physical activity
Actigraphy-quantified physical activity shows significant but variable prognostic value in CHF depending on the parameter considered. However, most CHF patients generally exhibit low levels of PA Figure 2 Outcomes of cardiovascular disease predicted by activity monitors.
and the studies demonstrate an inverse relationship between PA and CHF outcomes (Figure 2) . The studies have been classified by their observed primary outcomes into three categories: mortality, morbidity, and HRQoL.
Mortality
Five studies determined the prognostic value of AQPA in mortality. [40] [41] [42] 45, 48 Three studies looked specifically at mortality, 42, 45, 48 while two 40, 41 examined it in combination with intercurrent events (e.g. hospitalization).
In a Japanese CHF population, Izawa et al. 42 performed a multivariate analysis including brain natriuretic peptide, peak oxygen uptake, minute ventilation/carbon dioxide production (VE/VCO 2 ) slope, and number of steps taken per day into the model. This analysis revealed that number of steps, dichotomized into < _4889.4 and >4899.4 steps/day, was the only independent variable that had a strong significant predictive ability for mortality. Patients with < _4889.4 steps/day had a mortality of 88%, 25% points higher than that of the comparison group. Similarly, in a retrospective analysis of a Western CHF population, Loprinzi reported that an increase in AQPA by 60 min per day reduced the risk of all-cause mortality by 35%. 48 Conraads et al. 40 observed a similar improvement, showing a 5% relative risk reduction in mortality or CHF-related hospitalization with each 10-min increase in PA. Finally, Melin et al. 45 observed the predictive value of PA variability in CHF as determined by actigraphy. Skewness, indicating high PA recorded in one period and not others, was shown to be a significant predictor of mortality. Melin et al. 45 also added skewness to the Heart Failure Survival Score. The score, being one of the most validated prediction models in CHF, 57,58 was independently associated with death incidence in the studied population with a c-index (area under the receiver-operating characteristic curve) of 0. 71. 45 This was improved to 0.74 on addition of peak 3-h skewness, showing that AQPA had an incremental predictive value in this CHF population. Similarly, Conraads et al. added AQPA to the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity programme risk score. 59 This improved its predictive ability of death or CHF-related hospitalization from a c-index of 0.61 to 0. 65. 40 Morbidity Five studies focused on cognitive function in CHF patients. [35] [36] [37] [38] [39] Four studies investigated AQPA's relationship to hospitalizations and other intercurrent events in CHF, 40, 41, 46, 49 and two determined the ability of AQPA in predicting NYHA functional class. 44, 50 Alosco et al. also found AQPA was predictive of cognitive function independent of anatomical or physiological changes; daily step count was associated with attention and executive function (b = 0.31, P = 0.03) and language ability (b = 0.35, P = 0.01). This was the only study to show prognostic value on memory, specifically episodic memory (b = 0.27, P = 0.049). 35 Fulcher et al. also showed an independent predictive value of daily step count on global cognitive function (b = 0.28, P < 0.01), attention and executive function (b = 0.29, P < 0.01), and processing speed (b = 0.22, P < 0.05). However, this study showed no predictive value for memory tests (b = 0.12, P = 0.057). 39 Alosco et al. 36 further reported that a lower step count (b = 0.17, P = 0.057) and less time spent in Matthew's moderate activity (b = 0.19, P < 0.05) at baseline predicted attention and executive function up to 12 months later. In another study by the same group, decreases in either LIPA and MVPA over 12 weeks also predicted decline in attention and executive function. 37 Actigraphy-quantified physical activity significantly predicted risk of intercurrent events following CHF diagnosis. In these follow-up studies, Conraads et al. 40 showed 3% relative risk reduction for CHFrelated hospitalization with each 10-min increase in PA. This was consistent with findings from a Japanese population, with Miyahara et al. 49 showing a six-fold higher CHF-related hospitalization rate in low activity patients when compared with those who were physically active. This study also showed total PA to be the only significant predictor of rehospitalization on multivariate analysis [odds ratio (OR) 0.65, P = 0.03] and LIPA to best predict CHF rehospitalization (OR 0.60, P = 0.03). However, while Waring et al. 46 showed that patients with lower PA had a higher OR of readmission within 30 days, ranging from 4.8 to 16.9 over the 4 weeks of data collection, this study showed higher-intensity PA (defined as VMUs > _3000) to be the predictive parameter for CHF rehospitalization, and not LIPA as seen in Miyahara et al. 49 Finally, Howell et al. 41 considered multiple nonelective intercurrent events including mortality, hospitalizations, emergency department visits, intercurrent illness, and outpatient procedures. Inclusion of the magnitude of the most active 6-min block of the day in multivariate analysis was enough to significantly predict these events (hazard ratio 2.73, 95% confidence interval 1.10-6.77; P = 0.03), although its predictive value for individual events was not specified. Actigraphy-quantified physical activity was also able to predict NYHA functional class. Lower average daily accelerometer units and hours active per day was shown by Snipelisky et al. 50 to be associated with higher NYHA class. Jehn et al. 44 observed time spent at two walking speeds: 'walking' (0-80 m/min) and 'fast walking' (83-115 m/min). 'Total walking', 'walking' and 'fast walking' duration could differentiate between NYHA Class I and III, II and III (both P = 0.001) but not I and II. Importantly, monitoring for a duration of only 4 days for 'fast walking' was enough for a specificity and sensitivity of 74% in discriminating moderate CHF (NYHA class III).
Health-related quality of life Five studies predicted HRQoL outcomes based on AQPA. 38 
Discussion Physical activity measurement methods
While videotaping and counting steps or other activity measures is arguably the 'gold standard' for quantifying PA, this is clearly only feasible in a controlled laboratory setting and not applicable in quantifying patients' day-to-day activities. As mentioned previously, current studies commonly use self-reported assessments, ranging from questionnaires to patient diaries. These methods face subjective errors, which can be overcome by objective quantification of PA using actigraphy. However, these devices too have limitations (e.g. inability to distinguish between different sedentary activities). A range of monitors and data analysis methods exist, making comparison between studies difficult. Furthermore, one weakness of AQPA is the inability to analyse data based on situational context which may be resolved using pattern recognition and machine learning. This review will make recommendations to ease future efforts in the field.
Time points of physical activity measurements
Most studies took PA measurements from a single baseline period, characterizing patient activity levels at the time of study inclusion 35, 38, 39, [42] [43] [44] [45] [46] [47] [48] 60 or following intervention. 40 Only two studies by Alosco et al. quantified PA at two distinct periods, observing patient PA at baseline and 12 months 36 and at baseline and 12 weeks in a different study. 37 This may be due to the relatively high cost of actigraphy, limiting AQPA sampling. We believe that multiple measurements of PA are valuable as AQPA trends potentially contain prognostic value; further obtaining repeat measurements is realistic as AQPA is becoming more feasible. For example, large-scale objective measurement of PA is now increasingly incorporated in large surveys (e.g. UK Biobank, 61 US NHANES 62 ). Measurements of short time periods appear feasible in allowing discrimination of patients at risk of poor cardiovascular outcomes, with most studies included in this review using a time period of seven days [35] [36] [37] [38] [39] 42, 45, 47, 48 or including patients if they had at least three valid days of wear. [35] [36] [37] [38] [39] 44, 45 It must be appreciated that PA in CHF patients is not a static but a dynamic parameter that changes with time and health status. While it is promising that cross-sectional AQPA can predict risk of negative CHF outcomes, this merely reinforces the progression of patients with poorer health and functional status towards poorer outcomes. Physical activity decline over 12 weeks, independent of absolute PA quantity, was shown by Alosco et al. 37 to predict poorer cognitive function in CHF patients. Quantifying the rate of decline might prove to be more useful in determining and predicting disease severity and outcomes.
Defining levels of physical activity Thresholds which define PA levels differ between populations, most noticeably between paediatric and adult populations. Thresholds Figure 3 Recommendations for future research.
vary because of differences in the calibration samples and/or protocols. It should be noted that no single regression equation is able to accurately predict energy expenditure on PA, nor is any set of cut-off points able to accurately quantify time spent in different intensity categories across a wide range of activities. 63 Multiple thresholds were used by studies despite only including adult patients. Notably, thresholds used by the included studies are taken from calibration studies in non-CHF populations in laboratory environments. 53 To allow for quantitative analysis of the prognostic impact of AQPA in the future, these definitions must be standardized in future studies, with specific thresholds tailored to different diseases.
The recent move to accelerometers that store high-resolution raw acceleration signals in non-proprietary units provides opportunities to improve the characterization of PA and device comparability. 62 Presently, all studies included have utilized AQPA thresholds to categorize patients, followed by the observation of the prognostic impact of these categories on CVD outcomes. The categorization of patients based only on AQPA thresholds indicates the potentially missed opportunity of data optimization, as the wealth of data generated could contain more nuanced relationships between PA and CVD outcome. For example, AQPA be incorporated as a continuous statistic in survival analysis, providing a more precise predictive value in future prognostic algorithms.
Prognostic impact of actigraphy-quantified physical activity in cardiovascular disease
This systematic review has shown that AQPA has an independent prognostic value for mortality, morbidity, and HRQoL outcomes in CHF patients, extending the studies discussed above. This similar conclusion is unsurprising, with the unique difference being the objective PA measurement method, facilitating more accurate and precise measures of PA.
Mortality
Actigraphy-quantified physical activity has been shown to have independent predictive value for mortality in CHF. In line with the physiological benefits of PA 8 and consistent with previous studies using subjective PA measures, greater levels of AQPA show better prognosis in CHF mortality risk. Additionally, high variability in AQPA (i.e. intervening epochs of sedentary behaviour between LIPA and MVPA periods) was also predictive of greater mortality. 45 This suggests that quantity is not the only characteristic of AQPA that has prognostic value in CHF, and it behoves future studies to observe nuances in AQPA data when considering its prognostic value in CHF and CVD. The addition of AQPA to existing risk scores is a potential application of PA data, providing it adds value to and is not seen as burdensome compared with existing risk assessments. While only two studies investigated and observed enhanced predictive abilities of risk scores 40, 45 this could pave the way for a convenient and non-invasive method of quantifying risk in the future.
Morbidity
As with mortality, AQPA has independent predictive value for morbidity, particularly towards cognitive function, intercurrent events, and functional classification.
While cognitive impairment is a common morbidity in CHF patients, its aetiology has not been well-elucidated but is thought to be related to structural alterations [64] [65] [66] [67] and cerebral perfusion. 60, 67 As discussed in the introduction, PA causes physiological changes in cardiovascular parameters, including vascular dilatation, which could contribute to increased cerebral perfusion. AQPA provides an easy, non-invasive method to provide objective values to predict such changes and intervene earlier in patients at risk of such impairment. This too holds true for non-fatal intercurrent events and functional classification. Actigraphy-quantified physical activity provides an objective method to predict the risk of individual patients. From a clinical perspective, this may allow additional resources to be allocated to high-risk patients, with aims to reduce functional impairment and unplanned visits to hospital.
Health-related quality of life Across the studies, there exists a positive correlation between PA and HRQoL, with sedentary behaviour resulting in poorer HRQoL overall. It was not possible to make quantitative comparisons between studies due to the variety of instruments used, including the SF-12, SF-36, MLHF, and the CDC HRQoL measure. However, it should be noted that these HRQoL instruments are based on patient reporting, thus incurring a psychological element in their reports. It is uncertain to what extent their reporting is attributed to the actual physiological limitation of CHF and the psychological perception of their disease. 68 Though AQPA can quantify the decrease in PA, the magnitudes attributable to disease or patient perception have not been elucidated. The relationship between AQPA and physical function should be examined further.
Suggestions for future research
Although actigraphy has been used in research for over 20 years, its clinical application is still relatively novel due to limitations discussed above. Based on these, we suggest improvements to this promising field of research ( Figure 3) .
Actigraphy-quantified physical activity measurement
Current threshold definitions are based on healthy populations in laboratory-based validation studies. Physical activity limitations vary with pathology and these quantitative definitions may not be representative when applied to patient populations. These levels may also lack sensitivity to stratify patients who are all physically limited and may explain why most studies found low activity levels in their cohorts. Furthermore, dysfunction in PA occurs not only in CHF but in almost all CVDs, including coronary artery disease, arrhythmic, valvular, aortic, and peripheral vascular disease. Therefore, AQPA metrics and level thresholds need to be standardized, not for CVD as a whole but for individual diseases. used a single timepoint for AQPA measurement, further studies would benefit from multiple measurement timepoints to determine how changes in AQPA affect disease severity and outcomes. Actigraphy-quantified physical activity studies to investigate the effect of any CVD intervention could be performed to relate AQPA improvements with intervention, given that interventions including coronary artery bypass graft valve replacement/repair, or angioplasty are known to reduce mortality and morbidity. Actigraphy-quantified physical activity has also been shown to be related to cardiovascular biomarkers such as serum apolipoproteins in elderly patients 69 and may hold such a relationship in all CVD patients. Future studies should strive to use wireless technologies, which permit continuous data transfer, allowing for real-time analysis instead of post hoc determination of risk. Having shown that both quantitative and qualitative descriptors of AQPA have predictive ability for mortality, morbidity, and HRQoL, these studies should guide the next step in determining the temporal relationship between AQPA and CHF outcomes. For example, Conraads et al. 40 showed that early AQPA, defined as <30 days post-intervention, had significant impact on death or CHF hospitalization. It would be interesting to observe if such a chronological correlation holds for other time epochs. Studies should also consider devising methods to engage patients in the use of actigraphy data. Remote monitoring, without the input of nurses or doctors, has already been shown to have significant benefit in patients' clinical outcomes. 70 Given the tangible nature of the information provided by actigraphs, the information could empower them to engage in desirable activities solely due to awareness their personal PA levels or through methods such as gamification. 71 
Study design
Data management
Greater inclusion of actigraphy in clinical practice represents diagnostic, prognostic and management potential. However, with this comes logistical and analytical challenges-large quantities of data are generated with data being continually recorded over the measurement period. In larger epidemiological studies, this can run into the region of terabytes even if recorded for a week. Current strategies of big data management and analytics in CVD have been reviewed here. 72, 73 Application of 'smart' algorithms could be valuable for predicting morbidity in CHF patients. Machine learning is increasingly applied to various industries, including healthcare. Although still controversial due to data protection issues, machine learning has been shown to be an accurate means of identifying at-risk patients in both inpatient (e.g. acute kidney injury 74 ) and outpatient (e.g. breath sound telemonitoring predicting chronic obstructive pulmonary disease exacerbation 75 ) non-CVD contexts. Current morbidity and mortality risk scores are static and rely on fixed equations. Though extensively validated, these scores are decades old and may no longer represent the population today. 'Smart' algorithms on the other hand can evolve constantly with each patient added to the database, allowing dynamic characterizations of patients. Actigraphy-quantified physical activity shows longitudinal predictive value for cognitive function and mortality and might be incorporated into these algorithms to identify at-risk patients prior to decline. Earlier identification would allow prompt intervention and prevention of impairment.
Conclusion
Actigraphy-quantified physical activity is increasingly feasible with advancements and integration of technology into clinical practice. Early studies show clear predictive ability of these objectively measured PA parameters on mortality, morbidity, and HRQoL, with poorer prognosis associated with lower free-living PA. The results are consistent with current established knowledge and mirror findings from self-reported PA measures but have an advantage in providing quantifiable values. This objective data may therefore play a role in predicting morbidity and mortality outcomes in CHF patients and may also provide more accurate risk stratification through complementing pre-existing risk scores. There needs to be increased technology adoption in CVDs besides HF. Increased use of actigraphy, potentially with inclusion of commercial devices, will result in greater data generation, making big data strategies relevant to realize its full prognostic potential.
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